The Lausanne University Hospital (CHUV) has just inaugurated a cell production facility for immunotherapy on the Biopôle site in Epalinges, in the canton of Vaud. A major breakthrough in oncology, immunotherapy aims at directly stimulating a patient’s immune response to tumor cells by activating certain white blood cells. Excellent clinical results were reported against cancers considered to be incurable. This highly specialized lab, which will be fully operational next summer, will offer new hope to patients when the standard treatments are not effective.

The new facility will operate in close collaboration with the Ludwig institute for cancer research (LICR) based at the University of Lausanne (UNIL). Strong synergies will also be developed with AGORA, the future building dedicated to cancer research. Currently under construction on the CHUV campus, AGORA is poised to become a center of excellence that will attract top specialists in the area of cancer research. It will accommodate 300 researchers and clinicians from CHUV, UNIL and EPFL as of 2018.